Pharmacogenomics can improve antipsychotic treatment in schizophrenia

Frontiers of Medicine

Volumn 7, Issue 2, 2013, Pages 180-190

  Xu, Qingqing ^a,b   Wu, Xi ^a,b   Xiong, Yuyu ^a,b   Xing, Qinghe ^c   He, Lin ^a,b,c   Qin, Shengying ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai GenomePilot Institutes for Genomics and Human Health   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

antipsychotics; epigenetics; pharmacogenomics; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

GENETIC POLYMORPHISM; GENETICS; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; SCHIZOPHRENIA; METHODOLOGY; REVIEW;

ANTIPSYCHOTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 84894352988     PISSN: 20950217     EISSN: 20950225     Source Type: Journal    
DOI: 10.1007/s11684-013-0249-3     Document Type: Review

References (78)

1. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009; 35(1): 5–8
2. Fletcher PC, Frith CD. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 2009; 10(1): 48–58
3. Phan SV, Kreys TJ. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy 2011; 31(10): 1017–1030
4. Hovington CL, Lepage M. Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother 2012; 12(1): 53–69
5. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7(1): 9–37
6. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12(8): 707–747
7. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363(4): 301–304
8. Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J, Zhang F, Chen J, Zhou G, Ji W, Li B, Xu Y, Liu D, Wang P, Yang P, Liu B, Sun W, Wan C, Qin S, He G, Steinberg S, Cichon S, Werge T, Sigurdsson E, Tosato S, Palotie A, Nöthen MM, Rietschel M, Ophoff RA, Collier DA, Rujescu D, Clair DS, Stefansson H, Stefansson K, Ji J, Wang Q, Li W, Zheng L, Zhang H, Feng G, He L. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet 2011; 43(12): 1224–1227
9. Yue WH, Wang HF, Sun LD, Tang FL, Liu ZH, Zhang HX, Li WQ, Zhang YL, Zhang Y, Ma CC, Du B, Wang LF, Ren YQ, Yang YF, Hu XF, Wang Y, Deng W, Tan LW, Tan YL, Chen Q, Xu GM, Yang GG, Zuo XB, Yan H, Ruan YY, Lu TL, Han X, Ma XH, Wang Y, Cai LW, Jin C, Zhang HY, Yan J, Mi WF, Yin XY, Ma WB, Liu Q, Kang L, Sun W, Pan CY, Shuang M, Yang FD, Wang CY, Yang JL, Li KQ, Ma X, Li LJ, Yu X, Li QZ, Huang X, Lv LX, Li T, Zhao GP, Huang W, Zhang XJ, Zhang D. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet 2011; 43(12): 1228–1231
10. Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011; 14(2): 269–284
11. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010; 55(3): 117–125
12. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 2010; 10(1): 43–57
13. Guo X, Fang M, Zhai J, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z, Ma C, Guo T, Xie S, Twamley EW, Jin H, Zhao J. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl) 2011; 216(4): 475–484
14. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 2012; 13(11): 1545–1573
15. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196(6): 434–439
16. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, Wampers M, Scheen A, Peuskens J, van Winkel R. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101(1–3): 295–303
17. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008; 21(1): 70–83
18. Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci 2011; 65(1): 3–19
19. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9(5): 442–473
20. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012; 27(1): 55–67
21. Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, Tateishi T, Kondo T, Kaneko S. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57(5): 569–575
22. Gunes A, Spina E, Dahl ML, Scordo MG. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30(5): 628–633
23. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001; 57(9): 671–675
24. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010; 66(11): 1109–1117
25. Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147(3): 300–305
26. Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, de Vries R, Kaneko S. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 2003; 25(3): 287–293
27. Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003; 43(2): 122–127
28. Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007; 21(8): 837–842
29. Du J, Xu Y, Duan S, Zhang A, Xuan J, Wang L, Yu L, Wang H, Li X, Feng G, He L, Xing Q. A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(7): 1200–1204
30. Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 2007; 32(2): 161–167
31. Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W, Boonleang J, Wongnawa M, Rujimamahasan N, Pipatrattanaseree W. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther 2012; 37(2): 221–225
32. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299(3): 825–831
33. Du J, Zhang A, Wang L, Xuan J, Yu L, Che R, Li X, Gu N, Lin Z, Feng G, Xing Q, He L. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 2010; 24(7): 1115–1120
34. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL, Thelma BK. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005; 75(1): 21–26
35. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44(5): 439–446
36. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276(2): 658–666
37. Bozikas VP, Papakosta M, Niopas I, Karavatos A, Mirtsou-Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 2004; 14(1): 39–44
38. Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E. Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 2005; 587(1–2): 59–66
39. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Ozawa S, Sawada J. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004; 308(1): 300–306
40. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C- > A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47(4): 445–449
41. Kootstra-Ros JE, Smallegoor W, van der Weide J. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 2005; 42(Pt 3): 216–219
42. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97(7): 3473–3478
43. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001; 2(1): 51–64
44. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75(1): 13–33
45. Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, Meng J, Zhang A, Qin S, He L. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006; 7(7): 987–993
46. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008; 42(11): 884–893
47. Consoli G, Lastella M, Ciapparelli A, Catena Dell’Osso M, Ciofi L, Guidotti E, Danesi R, Dell’Osso L, Del Tacca M, Di Paolo A. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 2009; 10(8): 1267–1276
48. Skogh E, Sjödin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31(1): 4–9
49. Kuzman MR, Medved V, Bozina N, Grubišin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J 2011; 11(1): 35–44
50. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010; 50(6): 659–666
51. Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U. Carriers of the UGT1A4 142T > G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010; 66(5): 465–474
52. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee MLT, Xiao T, Papp A, Wang DX, Sadée W. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104(51): 20552–20557
53. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O’Donovan MC, Nakamura J, Ozaki N, Iwata N. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008; 9(10): 1437–1443
54. Zahari Z, Teh LK, Ismail R, Razali SM. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia. Psychiatr Genet 2011; 21(4): 183–189
55. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, Duan S, Xu M, Gao R, Qin W, Gao J, Meng J, He L. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007; 10(5): 631–637
56. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225(3): 1068–1072
57. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005; 25(1): 6–11
58. Xuan JK, Zhao XZ, He G, Yu L, Wang L, Tang W, Li XW, Gu NF, Feng GY, Xing QH, He L. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008; 33(2): 305–311
59. Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S, Mertens J, Terrière D, Costa DC, Ell PJ, Kerwin RW. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 1998; 173(3): 236–241
60. Parsons MJ, D’Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The-1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004; 56(6): 406–410
61. Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry 2007; 61(2): 167–173
62. Benmessaoud D, Hamdani N, Boni C, Ramoz N, Hamon M, Kacha F, Gorwood P. Excess of transmission of the G allele of the - 1438A/G polymorphism of the 5-HT(2A) receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008 May 30; 8:40
63. Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009; 29(1): 65–68
64. Popp J, Leucht S, Heres S, Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009; 9(1): 71–77
65. Hill MJ, Reynolds GP. Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics 2011; 12(5): 727–734
66. Davies MA, Setola V, Strachan RT, Sheffler DJ, Salay E, Hufeisen SJ, Roth BL. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 2006; 6(1): 42–51
67. Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, Feng G, Xing Q, He L. The −1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008; 22(8): 904–909
68. Gu B, Wang L, Zhang AP, Ma G, Zhao XZ, Li HF, Feng GY, He L, Xing QH. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 2008; 18(8): 721–727
69. Wei Z, Wang L, Xuan J, Che R, Du J, Qin S, Xing Y, Gu B, Yang L, Li H, Li J, Feng G, He L, Xing Q. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(3): 547–551
70. Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 2012; 73(8): 1077–1086
71. Kuzman MR, Medved V, Bozina N, Grubišin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J 2011; 11(1): 35–44
72. Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10(5): 639–651
73. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16(1): 76–85
74. Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011; 16(3): 321–332
75. Ingelman-Sundberg M, Gomez A. The past, present and future of pharmacoepigenomics. Pharmacogenomics 2010; 11(5): 625–627
76. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005; 24(54): 8061–8075
77. Hammons GJ, Yan-Sanders Y, Jin B, Blann E, Kadlubar FF, Lyn-Cook BD. Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human livers. Life Sci 2001; 69(7): 839–845
78. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006; 66(18): 9090–9098